SERPINA1

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Saudi Arabia is advancing four battery energy storage projects totaling 2,000 MW and 8,000 MWh, backed by more than SAR4.35 billion in commitments as the kingdom builds large-scale storage capacity to support renewable power across Makkah, Hail and Qassim. Representative image.

Saudi Arabia signs $1.16bn battery deals for 2GW and 8GWh of grid storage

RMC Switchgears’ ₹344.10 crore order win, including ₹333.80 crore of PGVCL underground-cabling work, has lifted its unexecuted order backlog to about ₹1,188 crore even as the company navigates a sharp Q1 revenue decline. Representative image.

RMC Switchgears (NSE: RMC) wins Rs 344cr orders as Q1 revenue plunges 56%

Representative image of an offshore oil and gas platform in the Norwegian continental shelf, illustrating why Vår Energi ASA’s record Q1 2026 production, strong cash flow, and dividend outlook are drawing investor attention.

Ithaca Energy (LSE: ITH) lifts 2026 dividend as Rosebank moves toward first oil

Euler Motors’ new Palwal manufacturing capacity can produce up to 24,000 electric four-wheelers annually, strengthening its electric cargo vehicle expansion after FY26 revenue doubled to ₹402 crore and raising the stakes in India’s fast-growing commercial EV market. Representative image.

Can Euler Motors fill a 24,000-unit factory while moving toward breakeven?

Representative image illustrating gene-editing research as YolTech Therapeutics advances YOLT-202 into a Phase 2/3 trial, exploring a potential “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency.

Why YolTech Therapeutics believes YOLT-202 could become a “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency

YolTech Therapeutics receives FDA clearance to launch a Phase 2/3 trial of YOLT-202 for Alpha-1 Antitrypsin Deficiency. Discover what this means for gene editing.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF
Zynga

March 15, 2026